A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1

Key Inclusion Criteria: * Adults ≥ 18 years of age at the time of signing the informed consent. * Documented primary diagnosis of Narcolepsy Type 1 (NT1) according to the International Classification of Sleep Disorders-Third Edition (ICSD-3) criteria. * Willing and able to safely discontinue all prohibited medications, including medications for the treatment of narcolepsy. * Body Mass Index (BMI) within the range of 18 - 40 kg/m2 (inclusive). Key Exclusion Criteria: * Any other (besides narcolepsy) clinically relevant medical, behavioral, or psychiatric disorder that is associated with excessive daytime sleepiness or cataplexy. * History of myocardial infarction or significant cardiovascular disease, structural cardiac abnormalities, cardiomyopathy, congestive heart failure, cardiac arrhythmias, coronary artery disease, cerebrovascular disease (transient ischemic attack or stroke), or any other significant cardiac problem. * History of long QT Syndrome or Torsades de Pointes, or an immediate family history of sudden cardiac death. * History of pulmonary hypertension and/or valvulopathy. * History of epilepsy, convulsions, or seizures (excluding early childhood febrile seizures). * Significant history of head injury or head trauma. * Recent or active suicidal ideation or behavior * Current, or within the past year, diagnosis of substance abuse or dependence disorder (SUD) including alcohol abuse. * Narrow-angle glaucoma. * Severe renal or hepatic insufficiency. * Occupation…